Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us

 

 

 

Session 13  Poster Discussion
Poster Discussion: Antiretroviral Therapy: Long-Term Immunologic Outcomes
Wednesday, 2:30 - 3:30 pm
302-304

Discussants:
  Yves Levy
  Henri Mondor Hosp, Créteil, France

  Michael Lederman
  Case Western Reserve Univ, Cleveland, OH, USA
      609 Long-term Evolution of CD4+ Cell Counts in Patients Treated with HAART and Having a Plasma HIV RNA Persistently < 500 Copies/mL
V Le Moing1, Rodolphe Thiebaut*2, F Raffi3, P Dellamonica4, F Brun-Vézinet5, C Cheneau6, C Barennes2, F Al Kaied5, G Chêne2, C Leport5, and the APROCO/COPILOTE Study Group
1Ctr Hosp Univ Montpellier, France; 2INSERM U593, Bordeaux, France; 3Ctr Hosp Univ Nantes, France; 4Ctr Hosp Univ Nice, France; 5Ctr Hosp Univ Bichat, Paris, France; and 6Ctr Hosp Univ Strasbourg, France
      610 Immunologic Outcomes after Antiretroviral Therapy in HIV+ Subjects in ACTG 384
R Gandhi*1, E Chan2, J Spritzler2, D Asmuth3, B Rodriguez4, T Merigan5, M Hirsch1, R Shafer5, G Robbins1, R Pollard3, and the ACTG 384 Team
1Massachusetts Gen Hosp, Boston, USA; 2Harvard Sch of Publ Hlth, Boston, MA, USA; 3Univ of California, Davis, Med Ctr, USA; 4Case Western Reserve Univ, Cleveland, OH, USA; and 5Stanford Univ Med Ctr, CA, USA
      611 Long-term Immunologic Reconstitution (4 Years) in Spanish HIV-infected Patients on HAART in the PISCIS Cohort Study
A Esteve1, Angels Jaén*1, J Casabona1, J Miró2, M Riera3, E Ferrer4, C Tural5, F Segura6, L Force7, O Sued2, J Vilaró8, À Masabeu9, C Villalonga3, D Podzamczer4, B Clotet5, and PISCIS study group
1Ctr for Epidemiological Studies on HIV/AIDS in Catalonia, Badalona, Spain; 2Hosp Clin, IDIBAPS, Univ of Barcelona, Spain; 3Hosp de Son Dureta, Palma de Mallorca, Spain; 4Hosp de Bellvitge, Barcelona, Spain; 5Hosp Univ Germans Trias i Pujol, Badalona, Spain; 6Corp Parc Taulí de Sabadell, Spain; 7Hosp de Mataró, Spain; 8Hosp General de Vic, Spain; and 9Hosp de Palamós, Spain
      612 Effect of 7 Years of Potent Antiretroviral Therapy on CD4 T-lymphocyte Recovery
Gilbert Kaufmann*1, L Perrin2, M Opravil3, H Furrer4, M Cavassini5, B Hirschel6, P Vernazza7, E Bernasconi8, M Rickenbach9, M Battegay1, and Swiss HIV Cohort Study
1Basel Univ Hosp, Switzerland; 2Geneva Univ Hosp, Switzerland; 3Zurich Univ Hosp, Switzerland; 4Berne Univ Hosp, Switzerland; 5Div. of Infect. Dis., CHUV, Switzerland; 6Geneva Univ Hosp, Switzerland; 7St Gallen Hosp, Switzerland; 8Reg Hosp, Lugano, Switzerland; and 9Swiss HIV Cohort Study Data Ctr, Lausanne
      613 Despite Better Virologic Responses, South Africans Have Diminished CD4 T-cell Recovery after HAART
Michelle V Lisgaris*1, M Lederman1, W Stevens2, I Sanne2, J Gatell3, P Cahn4, A Landay5, S Schnittman6, T Kelleher6, and B Rodriguez1
1Case Western Reserve Univ, Ctr For AIDs Res, Cleveland, OH, USA; 2Univ of the Witwatersrand, Johannesburg, South Africa; 3Univ of Barcelona, Spain; 4Univ of Buenos Aires, Argentina; 5Rush Med Coll, Chicago, IL, USA; and 6Bristol-Myers Squibb, Wallingford, CT, USA